EGFR and neoplasm: First-line bevacizumab-based therapy represents the standard of care in RAS mutant mCRCs independently form the site of primary tumor and, more recently, has been proposed as more effective strategy in right-side mCRCs independently from RAS mutational status, based on the evidence that right-side, KRAS wild-type tumors have a lower benefit with first-line anti-EGFR agents [17,19].